REG-Millennium Partners, L.P. Form 8.3 - Mural Oncology plc
02/05/2025 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250502:nBw2Vp7Wga&default-theme=true
Form 8.3 - Mural Oncology plc
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE
1. KEY INFORMATION
(a) Full name of discloser Millennium International Management LP
(b) Owner or controller of interests and short positions disclosed, if
different from 1(a)
The naming of nominee or vehicle companies is insufficient. For a trust, the
trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form Mural Oncology plc
relates
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree, state this
and specify identity of offeror/offeree (Note 1)
(e) Date position held/dealing undertaken 01(st) May 2025
For an opening position disclosure, state the latest practicable date prior to
the disclosure
(f) In addition to the company in 1(c) above, is the discloser also making NO
disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class
of relevant securities of the offeror or offeree named in 1(c), copy table 2
for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or
offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security $0.01 ordinary shares (IE000LK2BOB4)
(Note 3)
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled 250,765 1.452% - -
(2) Cash-settled derivatives - - - -
(3) Stock-settled derivatives (including options) and agreements to purchase/ - - - -
sell
Total 250,765 1.452% - -
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any
open stock-settled derivative positions (including traded options), or
agreements to purchase or sell relevant securities, should be given on a
Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit
security
securities
(Note 5)
(USD)
IE000LK2BOB4 Purchase 200 2.58
IE000LK2BOB4 Purchase 3,394 2.60
IE000LK2BOB4 Purchase 1,596 2.61
IE000LK2BOB4 Purchase 200 2.59
IE000LK2BOB4 Sale 200 2.61
IE000LK2BOB4 Purchase 200 2.63
IE000LK2BOB4 Sale 30 2.58
IE000LK2BOB4 Purchase 125 2.60
IE000LK2BOB4 Sale 20 2.60
IE000LK2BOB4 Purchase 79 2.61
IE000LK2BOB4 Purchase 8 2.59
IE000LK2BOB4 Sale 161 2.59
IE000LK2BOB4 Sale 192 2.61
IE000LK2BOB4 Sale 14 2.59
Ap29
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price
relevant
description
e.g. opening/ closing a long/ short position, increasing/ reducing a long/
reference
per unit
security
e.g. CFD short position
securities
(Note 5)
(Note 6)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, purchasing, selling, varying Number Exercise Type Expiry Option
relevant
description e.g. call
etc.
of
price per
e.g.
date
money
security
option
securities
unit
American,
paid/
to which
European
received per unit
option
etc.
relates
(Note 6)
(ii) Exercise
Class of Product Exercising/ Number of Exercise
relevant
description
exercised
securities
price per
security
e.g. call
against
unit
option
(Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note
3)
Class of Nature of dealing Details Price per unit (if
relevant
e.g. subscription,
applicable)
security
conversion, exercise
(Note 5)
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the person
making the disclosure and any party to the offer or any person acting in
concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state “none”
(b) Agreements, arrangements or understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.
(c) Attachments
Is a Supplemental Form 8 attached? NO
Date of disclosure 02(nd) May 2025
Contact name Stephen Glasper
Telephone number +44 203 398 2166
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory
Information Service.
Ap31
NOTES ON FORM 8.3
1. See the definition of “connected fund manager” in Rule 2.2 of Part A of
the Rules.
2. See the definition of “interest in a relevant security” in Rule 2.5 of
Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.
3. See the definition of “relevant securities” in Rule 2.1 of Part A of
the Rules.
4. See the definition of “dealing” in Rule 2.1 of Part A of the Rules.
5. If the economic exposure to changes in the price of securities is limited,
for example, by virtue of a stop loss arrangement relating to a spread bet,
full details must be given.
6. See Rule 2.5(d) of Part A of the Rules.
7. If details included in a disclosure under Rule 8 are incorrect, they should
be corrected as soon as practicable in a subsequent disclosure. Such
disclosure should state clearly that it corrects details disclosed previously,
identify the disclosure or disclosures being corrected, and provide sufficient
detail for the reader to understand the nature of the corrections. In the case
of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rule 8 of the Rules. If in
doubt, consult the Panel.
References in these notes to “the Rules” are to the Irish Takeover Panel
Act, 1997, Takeover Rules, 2022.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20250502558351/en/
(https://www.businesswire.com/news/home/20250502558351/en/)
Millennium Partners, L.P.
Copyright Business Wire 2025Recent news on Mural Oncology
See all newsREG-Millennium Partners, L.P. Form 8.3 - Mural Oncology plc
AnnouncementREG-The Vanguard Group, Inc. Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
AnnouncementREG - Goldman Sachs & Co. Mural Oncology PLC - Form 8.3 - MURAL ONCOLOGY PLC
AnnouncementREG - Spirit Biosciences Mural Oncology PLC - Form 8.3 - Mural Oncology plc
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Mural Oncology plc
Announcement